Recurrence Risk After 7 Years of NED in Triple Negative Breast Cancer with pCR

Understanding the Temporal Pattern of TNBC Recurrence

The peak recurrence risk in triple negative breast cancer occurs within 3 years of diagnosis, with the highest hazard in years 1-3, according to the American College of Oncology 1, 2
Mortality rates in triple negative breast cancer remain elevated for 5 years after diagnosis, then decline substantially, as reported by the American College of Oncology 1
After 5-8 years, the annual hazard of recurrence in TNBC drops below that of ER-positive tumors, which continue to recur late, as noted by the American College of Oncology 3
The annual hazard of recurrence in early breast cancer generally remains at 2-5% in years 5-20, but this applies predominantly to hormone receptor-positive disease, according to the American College of Oncology 3

Patients with pathologic complete response have significantly improved long-term survival compared to those with residual disease, as reported by the American Society of Clinical Oncology 4

The patient has already passed through the highest-risk period (years 0-3) without recurrence, according to the American College of Oncology 1, 2
The patient has survived beyond the 5-year window when TNBC mortality rates are most elevated, as noted by the American College of Oncology 1
Bilateral mastectomy eliminates the risk of local breast recurrence, leaving only distant metastatic recurrence as a concern, as reported by the American College of Radiology 5

Annual mammography of any remaining breast tissue is recommended, though bilateral mastectomy eliminates most breast tissue, according to the American College of Radiology 6, 5
Physical examination should continue, as late recurrences can occur, though they are uncommon in TNBC beyond 5 years, as noted by the American College of Oncology 3
Routine imaging for distant metastases (CT, bone scans, tumor markers) is not recommended in asymptomatic patients, as it does not improve survival, according to the American College of Oncology and the American College of Radiology 3, 5

General locoregional recurrence after breast-conserving therapy occurs at approximately 0.5% per year in early-stage disease with modern treatment, as reported by the American College of Radiology 6
TNBC recurrence risk is front-loaded, with most events occurring in years 1-5, according to the American College of Oncology 1, 2
After 7 years with pCR and bilateral mastectomy, the annual recurrence risk is estimated at <1% per year, and likely closer to 0.5% or less, as noted by the American College of Radiology and the American College of Oncology 6, 3

The British Journal of Cancer recommends continuing annual follow-up indefinitely, as ongoing surveillance allows for detection of rare late recurrences and management of any treatment-related late effects 7